<a href="https://www.fiercebiotech.com/biotech/avalyn-plans-ipo-fund-phase-3-trials-inhaled-versions-approved-respiratory-drugs" hreflang="en">Avalyn plans IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs</a>
fiercebiotech.com·Apr 9, 2026
Avalyn Pharma plans to pursue an IPO to secure funding for advancing its inhaled lung condition drugs into phase 3 trials.
Avalyn Pharma's move toward an IPO to fund phase 3 trials highlights an investment opportunity in biotech companies developing innovative delivery methods for existing drugs, particularly in respiratory health. For a professional interested in healthtech and biotech, monitoring Avalyn Pharma's progress could provide insights into the viability and market potential of inhaled drug therapies, which may influence investment or partnership strategies in similar therapeutic innovations.